Table 3 Outcomes tested for an association with global African ancestry in African Americans from EAGLE BioVU
From: Towards a phenome-wide catalog of human clinical traits impacted by genetic ancestry
Outcome (n) | % or median (± SD) | OR or β (95 % CI or SE) | P-value |
|---|---|---|---|
Hypertension, baseline (n = 6,422) | 56 % | 0.81 (0.61 – 1.07) | 0.14 |
Hypertension, lifetime (n = 8,691) | 78 % | 0.81 (0.54 – 1.21) | 0.30 |
Type 2 diabetes (n = 1,356) | 12 % | 0.75 (0.52 – 1.08) | 0.12 |
Albumin (g/dL), serum (n = 8,094) | 4.05 (0.51) | 0.02 (0.04) | 0.67 |
Albumin creatinine ratio (mg/mmol) (n = 1,210) | 14.00 (861.08) | 0.01 (0.17) | 0.95 |
Albumin (mg/dL), urinary (n = 1,199) | 16.7 (640.2) | 0.04 (0.16) | 0.79 |
Blood urea nitrogen (mg/dL) (n = 10,111) | 11.00 (13.55) | 0.10 (0.90) | 0.92 |
Body mass index (kg/m2) (n = 9,247) | 27.25 (7.21) | −0.81 (0.50) | 0.10 |
Creatinine (mg/dL), serum (n = 10,288) | 0.88 (1.99) | −0.09 (0.13) | 0.50 |
Creatinine (g/kg/day), urinary (n = 172) | 70.00 (73.89) | −23.54 (38.74) | 0.54 |
Diastolic blood pressure (mm Hg), baseline (n = 10,025) | 76.00 (15.68) | −0.35 (1.05) | 0.74 |
Diastolic blood pressure (mm Hg), post-medication (n = 5,653) | 79.00 (10.06) | 0.01 (0.88) | 0.99 |
Diastolic blood pressure (mm Hg), pre-medication (n = 7,009) | 75.00 (11.28) | −0.37 (0.90) | 0.68 |
Glucose (mg/dL) (n = 9,918) | 96.00 (34.33) | −0.22 (2.30) | 0.92 |
Glycated hemoglobin (mg/dL) (n = 2,925) | 6.30 (1.80) | −0.15 (0.22) | 0.49 |
HDL-C (mg/dL) (n = 5,096) | 50.00 (16.99) | 1.09 (1.60) | 0.49 |
HDL-c (mg/dL) post-medication (n = 2,097) | 47.75 (16.55) | 2.74 (2.38) | 0.25 |
HDL-C (mg/dL), pre-medication (n = 4,273) | 51.00 (17.09) | 1.43 (1.73) | 0.41 |
Heart rate (beats per minute) (n = 783) | 76.00 (11.14) | 2.44 (2.58) | 0.35 |
Insulin (IU/mL) (n = 343) | 16.90 (74.36) | 11.67 (24.25) | 0.63 |
LDL-C (mg/dL), regardless of medication status | 99.00 (35.18) | 0.58 (3.31) | 0.86 |
LDL-C (mg/dL), post-medication | 96.00 (38.90) | −6.00 (5.55) | 0.28 |
LDL-C (mg/dL), pre-medication | 105.00 (39.70) | 3.52 (4.11) | 0.40 |
PR Interval (msec) (n = 781) | 159.00 (17.92) | 0.56 (4.16) | 0.89 |
QRS duration (msec) (n = 837) | 82.00 (8.65) | −7.45 (1.93) | 1.3x10-4 |
QT interval (msec) (n = 783) | 376.00 (27.84) | −9.66 (6.45) | 0.14 |
Systolic blood pressure (mm Hg), baseline (n = 10,025) | 125.00 (22.54) | 1.37 (1.50) | 0.36 |
Systolic blood pressure (mm Hg), post-medication (n = 5,653) | 132.00 (16.03) | −0.30 (1.40) | 0.83 |
Systolic blood pressure (mm Hg), pre-medication (n = 7,009) | 123.00 (16.38) | −0.06 (1.31) | 0.96 |
Total cholesterol (mg/dL), regardless of medication status (n = 5,439) | 175.00 (39.48) | −0.35 (3.57) | 0.92 |
Total cholesterol (mg/dL), post-medication (n = 2,150) | 173.50 (44.22) | −5.40 (6.31) | 0.39 |
Total cholesterol (mg/dL), pre-medication (n = 4,642) | 181.00 (44.86) | 0.73 (4.38) | 0.86 |
Triglycerides (mg/dL), regardless of medication status (n = 5,269) | 98.00 (69.46) | −5.70 (6.40) | 0.38 |
Triglycerides (mg/dL), post-medication (n = 2,115) | 110.00 (74.07) | −15.64 (10.62) | 0.14 |
Triglycerides (mg/dL), pre-medication (n = 4,445) | 97.00 (79.25) | −1.75 (7.93) | 0.83 |
Uric acid (mg/dL) (n = 2,465) | 5.40 (2.18) | −0.01 (0.28) | 0.97 |